Akouos soars 87% as Lilly nabs hearing loss gene therapy developer

Oct. 18, 2022 7:25 AM ETEli Lilly and Company (LLY)By: Ravikash, SA News Editor2 Comments

Eli Lilly and Company Research Laboratories. Lilly makes Medicines and Pharmaceuticals.

jetcityimage/iStock Editorial via Getty Images

Eli Lilly (NYSE:LLY) is acquiring hearing loss gene therapy maker Akouos (NASDAQ:AKUS) for ~$487M plus contingent value right (CVR) worth up to $610M.

Under the agreement, Lilly will begin a tender offer to acquire all the outstanding shares

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.